Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

Oral therapy showed dose-dependent increases in progranulin protein levels in both plasma and cerebrospinal fluid; >95% mean increase in progranulin levels in CSF, compared to baseline; favorable ...

Here are the top FTSE 100 Index shares to watch next week, including BT Group, BP, IAG, Marks and Spencer (MKS) and AstraZeneca ...

Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and ...

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...